Resources

This document states the outcome of Alexion Pharmaceuticals Australasia's application to include asfotase alfa on the Life Saving Drugs Program.

Health professionals can print this fact sheet and give it to patients who are starting treatment under the Life Saving Drugs Program.

This communique outlines the main points from discussion from the National Site of Recognition Steering Committee meeting including the next steps in the development of the National Site of Recognition for thalidomide survivors and their families.

Life Saving Drugs Program Expert Panel (LSDPEP) agenda for the 11th meeting on 18th February 2022.

This fact sheet provides information for participants of the Australian Thalidomide Survivors Support Program about the categories of goods and services which are eligible to be claimed under the Health Care Assistance Fund (HCAF).

This form is a template for health practitioners to provide evidence to support an eligible thalidomide survivor (patient) to receive support from the Extraordinary Assistance Fund (EAF) or the Health Care Assistance Fund (HCAF).

This factsheet provides information about how participants of the Australian Thalidomide Survivors Support Program can make a claim to the Health Care Assistance Fund (HCAF). The HCAF helps cover out-of-pocket health care expenses incurred as a direct result of thalidomide injuries.

This fact sheet provides information for participants of the Australian Thalidomide Survivors Support Program about the categories of goods and services which are eligible to be claimed under the Extraordinary Assistance Fund (EAF).

This fact sheet provides information about how participants of the Australian Thalidomide Survivors Support Program can make a claim to the Extraordinary Assistance Fund (EAF). The EAF helps cover the costs of goods and services to assist with activities of daily living.

Details of the second meeting of Steering Committee for the National Site of Recognition for thalidomide survivors and their families, held on 9 December 2021.

This executive summary of the TIS mid term evaluation report, completed in May 2021, summarises the interim findings from the independent evaluation of the TIS program 2018–19 to 2021–22.

This mid-term evaluation report, completed in December 2020, presents the interim findings from the independent evaluation of the short and medium-term outcome objectives for the TIS program 2018–19 to 2021–22.

This report, completed in July 2018, evaluates how effective the Tackling Indigenous Smoking (TIS) program has been and whether it’s on target to achieve its long-term goals.

This report summarises developments in the national bowel and cervical screening programs and the National Cancer Screening Register since the initial privacy impact assessment was done.

Treating physicians use this application form to apply for a patient to access LSDP medication for Gaucher disease for the first time, or after a break.

Treating physicians use this form to reapply each year for a patient to receive ongoing LSDP medication for MPS I.

Treating physicians use this form to reapply each year for a patient to receive ongoing LSDP medication for MPS II.

Treating physicians use this form to reapply each year for a patient to receive ongoing LSDP medication for Fabry disease.

Treating physicians use this form to reapply each year for a patient to receive ongoing LSDP medication for MPS IVA.

Treating physicians use this form to reapply each year for a patient to receive ongoing LSDP medication for MPS VI.

Treating physicians use this form to reapply each year for a patient to receive ongoing LSDP medication for Pompe disease.

Treating physicians use this form to reapply each year for a patient to receive ongoing LSDP medication for paroxysmal nocturnal haemoglobinuria.